TriSalus Life Sciences appointed veteran healthcare investor Michael Stansky to its board of directors, effective immediately. The addition enhances the board’s expertise in biotech investing and corporate governance.

Michael Stansky has spent over two decades in healthcare investing, focusing on biotech and life sciences companies. His experience includes participating in multiple funding rounds and serving on governance committees at emerging firms.

Stansky’s extensive network and capital-raising track record are expected to support TriSalus’s clinical development programs and strategic partnerships. Board and management anticipate his guidance will accelerate growth initiatives and funding strategies.